Citation | Zak, M; Mendonca, R; Balazs, M; Barrett, K; Bergeron, P; Blair, WS; Chang, C; Deshmukh, G; Devoss, J; Dragovich, PS; Eigenbrot, C; Ghilardi, N; Gibbons, P; Gradl, S; Hamman, C; Hanan, EJ; Harstad, E; Hewitt, PR; Hurley, CA; Jin, T; Johnson, A; Johnson, T; Kenny, JR; Koehler, MF; Bir Kohli, P; Kulagowski, JJ; Labadie, S; Liao, J; Liimatta, M; Lin, Z; Lupardus, PJ; Maxey, RJ; Murray, JM; Pulk, R; Rodriguez, M; Savage, S; Shia, S; Steffek, M; Ubhayakar, S; Ultsch, M; van Abbema, A; Ward, SI; Xiao, L; Xiao, Y Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem55:6176-93 (2012) [PubMed] Article |
---|
SMILES | CC(=O)N[C@H]1CC[C@@H](CC1)n1c(C)nc2cnc3[nH]ccc3c12 |r,wU:4.3,wD:7.10,(.89,-9.34,;.16,-10.7,;-1.39,-10.74,;1.04,-11.96,;.38,-13.35,;1.11,-14.7,;.3,-16.02,;-1.24,-15.97,;-1.97,-14.62,;-1.16,-13.31,;-2.04,-17.29,;-3.58,-17.11,;-4.34,-15.77,;-4.22,-18.52,;-3.08,-19.56,;-3.09,-21.1,;-1.76,-21.88,;-.42,-21.11,;1.04,-21.61,;1.95,-20.37,;1.06,-19.11,;-.41,-19.58,;-1.74,-18.8,)| |